Publications 2020

Fosså A, Smeland KH, Fluge Ø, Tronstad KJ, Loge JH, Midttun Ø, Ueland PM, Kiserud CE (2020)
Metabolic analysis of amino acids and vitamin B6 pathways in lymphoma survivors with cancer related chronic fatigue
PLoS One, 15 (1), e0227384
DOI 10.1371/journal.pone.0227384, PubMed 31923274

Jakobsen LH, Ellin F, Smeland KB, Wästerlid T, Christensen JH, Jørgensen JM, Josefsson PL, Øvlisen AK, Holte H, Blaker YN, Grauslund JH, Bjørn J, Molin D, Lagerlöf I, Smedby KE, Colvin K, Thanarajasingam G, Maurer MJ, Habermann TM, Song KW, Zhu KY, Gerrie AS, Cheah CY, El-Galaly TC (2020)
Minimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patients
Br J Haematol, 189 (4), 661-671
DOI 10.1111/bjh.16425, PubMed 32017050

Publications 2019

Bersvendsen HS, Haugnes HS, Dahl AA, Fagerli UM, Fluge Ø, Holte H, Seland M, Wilsgaard T, Smeland KB, Kiserud CE (2019)
Sexual function in long-term male lymphoma survivors after high-dose therapy with autologous stem-cell transplantation
Bone Marrow Transplant, 55 (5), 891-905
DOI 10.1038/s41409-019-0745-4, PubMed 31745250

Bersvendsen HS, Haugnes HS, Fagerli UM, Fluge Ø, Holte H, Smeland KB, Wilsgaard T, Kiserud CE (2019)
Lifestyle behavior among lymphoma survivors after high-dose therapy with autologous hematopoietic stem cell transplantation, assessed by patient-reported outcomes
Acta Oncol, 58 (5), 690-699
DOI 10.1080/0284186X.2018.1558370, PubMed 30696346

Biccler JL, Glimelius I, Eloranta S, Smeland KB, Brown PN, Jakobsen LH, Frederiksen H, Jerkeman M, Fosså A, Andersson TML, Holte H, Bøgsted M, El-Galaly TC, Smedby KE (2019)
Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study
J Clin Oncol, 37 (9), 703-713
DOI 10.1200/JCO.18.01652, PubMed 30726176

Fosså A, Smeland K, Fagerli UM, Galleberg RB, Bersvendsen HS, Holte H (2019)
Brentuximab vedotin in relapsed or refractory classical hodgkin lymphoma: real life experience in Norway 2011-2016
Acta Oncol, 59 (1), 101-105
DOI 10.1080/0284186X.2019.1652765, PubMed 31429371

Simensen VC, Smeland KB, Kiserud CE, Dahl AA, Bersvendsen HS, Fluge Ø, Fagerli UM, Fosså A (2019)
Survivors' knowledge of their diagnosis, treatment and possible late adverse effects after autologous stem cell transplantation for lymphoma
Acta Oncol, 58 (9), 1315-1322
DOI 10.1080/0284186X.2019.1637538, PubMed 31286808

Publications 2018

Smeland KB, Loge JH, Aass HCD, Aspelin T, Bersvendsen H, Bolstad N, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Holte H, Lund MB, Murbræch K, Reinertsen KV, Stenehjem JS, Kiserud CE (2018)
Chronic fatigue is highly prevalent in survivors of autologous stem cell transplantation and associated with IL-6, neuroticism, cardiorespiratory fitness, and obesity
Bone Marrow Transplant, 54 (4), 607-610
DOI 10.1038/s41409-018-0342-y, PubMed 30262906

Publications 2017

Seland M, Smeland KB, Bjøro T, Falk RS, Fosså SD, Gjesdal CG, Godang K, Holte H, Svartberg J, Syversen U, Bollerslev J, Kiserud CE (2017)
Bone mineral density is close to normal for age in long-term lymphoma survivors treated with high-dose therapy with autologous stem cell transplantation
Acta Oncol, 56 (4), 590-598
DOI 10.1080/0284186X.2016.1267870, PubMed 28077016

Smeland KH (2017)
Overlevelse og seneffekter etter lymfombehandling
Tidsskr Nor Laegeforen, 137 (6), 470
DOI 10.4045/tidsskr.16.1111, PubMed 28332807

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy SO, Wethal T, Kiserud CE, Samersaw-Lund MB (2017)
Obstructive and restrictive pulmonary dysfunction in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation
Acta Oncol, 57 (6), 773-781
DOI 10.1080/0284186X.2017.1406137, PubMed 29171324

Publications 2016

Kiserud CE, Fagerli UM, Smeland KB, Fluge Ø, Bersvendsen H, Kvaløy S, Holte H, Dahl AA (2016)
Pattern of employment and associated factors in long-term lymphoma survivors 10 years after high-dose chemotherapy with autologous stem cell transplantation
Acta Oncol, 55 (5), 547-53
DOI 10.3109/0284186X.2015.1125015, PubMed 27123741

Murbraech K, Holte E, Broch K, Smeland KB, Holte H, Rösner A, Lund MB, Dalen H, Kiserud C, Aakhus S (2016)
Impaired Right Ventricular Function in Long-Term Lymphoma Survivors
J Am Soc Echocardiogr, 29 (6), 528-36
DOI 10.1016/j.echo.2016.02.014, PubMed 27038515

Murbraech K, Wethal T, Smeland KB, Holte H, Loge JH, Holte E, Rösner A, Dalen H, Kiserud CE, Aakhus S (2016)
Valvular Dysfunction in Lymphoma Survivors Treated With Autologous Stem Cell Transplantation: A National Cross-Sectional Study
JACC Cardiovasc Imaging, 9 (3), 230-9
DOI 10.1016/j.jcmg.2015.06.028, PubMed 26897666

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Østenstad B, Kvaløy S, Holte H (2016)
A national study on conditional survival, excess mortality and second cancer after high dose therapy with autologous stem cell transplantation for non-Hodgkin lymphoma
Br J Haematol, 173 (3), 432-43
DOI 10.1111/bjh.13965, PubMed 26914167

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Thorsen L, Arbo I, Jones LW, Aakhus S, Lund MB, Kiserud CE (2016)
Cardiorespiratory fitness in long-term lymphoma survivors after high-dose chemotherapy with autologous stem cell transplantation
Br J Cancer, 115 (2), 178-87
DOI 10.1038/bjc.2016.180, PubMed 27351215

Stenehjem JS, Smeland KB, Murbraech K, Holte H, Kvaløy S, Wethal T, Kiserud CE, Lund MB (2016)
Diffusing capacity impairment is prevalent in long-term lymphoma survivors after high-dose therapy with autologous stem cell transplantation
Bone Marrow Transplant, 52 (4), 646-649
DOI 10.1038/bmt.2016.338, PubMed 27991891

Publications 2015

Murbraech K, Smeland KB, Holte H, Loge JH, Lund MB, Wethal T, Holte E, Rösner A, Dalen H, Kvaløy S, Falk RS, Aakhus S, Kiserud CE (2015)
Heart Failure and Asymptomatic Left Ventricular Systolic Dysfunction in Lymphoma Survivors Treated With Autologous Stem-Cell Transplantation: A National Cross-Sectional Study
J Clin Oncol, 33 (24), 2683-91
DOI 10.1200/JCO.2015.60.8125, PubMed 26169610

Smeland KB, Kiserud CE, Lauritzsen GF, Fagerli UM, Falk RS, Fluge Ø, Fosså A, Kolstad A, Loge JH, Maisenhölder M, Kvaløy S, Holte H (2015)
Conditional survival and excess mortality after high-dose therapy with autologous stem cell transplantation for adult refractory or relapsed Hodgkin lymphoma in Norway
Haematologica, 100 (6), e240-3
DOI 10.3324/haematol.2014.119214, PubMed 25682605

Publications 2013

Smeland KB, Kiserud CE, Lauritzsen GF, Blystad AK, Fagerli UM, Fluge Ø, Fosså A, Hammerstrøm J, Kolstad A, Loge JH, Maisenhølder M, Østenstad B, Kvaløy S, Holte H (2013)
High-dose therapy with autologous stem cell support for lymphoma in Norway 1987-2008
Tidsskr Nor Laegeforen, 133 (16), 1704-9
DOI 10.4045/tidsskr.13.0243, PubMed 24005706

Smeland KB, Kiserud CE, Lauritzsen GF, Fosså A, Hammerstrøm J, Jetne V, Kolstad A, Kvalheim G, Loge JH, Løkeland T, Tangen JM, Holte H, Kvaløy S (2013)
High-dose therapy with autologous stem cell support for lymphoma--from experimental to standard treatment
Tidsskr Nor Laegeforen, 133 (16), 1735-9
DOI 10.4045/tidsskr.13.0319, PubMed 24005713